ArticlebioRxiv : the preprint server for biology2026
Spatiotemporal dynamics of Mcl-1 abundance and its influence on apoptosis susceptibility.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Bcl-2 protein family defines cellular competence for mitochondrial outer membrane permeabilization (MOMP) and apoptotic cell death. In proliferating cells, the Bcl-2 family member Mcl-1 accumulates across the cell cycle and confers trans-mitotic resistance to extrinsic apoptosis. We show here that Mcl-1, but not Bcl-xL, additionally undergoes a coordinated redistribution from the cytosol to mitochondria, concomitant with its over-proportional accumulation late in the cell cycle. Live-cell monitoring of Mcl-1 dynamics at single-cell resolution, combined with mathematical modelling, enabled us to quantify that Mcl-1 redistribution substantially contributes to elevating MOMP thresholds. Furthermore, we found that Mcl-1 accumulation and redistribution act concomitantly but independently to increase MOMP thresholds as cells approach mitosis and this elevated resistance is reset in daughter cells after division. Notably, heterogeneities in Mcl-1 abundance and subcellular distribution are pronounced even among isogenic cells within the same cell-cycle phase, and thus contribute to substantial cell-to-cell variability in MOMP susceptibility. Analysis of colorectal cancer tissue samples showed that variability in Mcl-1 expression and distribution is likewise prominent between cells in patient tumors and were predicted to drive intra-tumour heterogeneity in responses to treatments that induce MOMP. Overall, we demonstrate how changes in Mcl-1 amounts and localisation integrate with cell-cycle progression to modulate apoptotic susceptibility, thereby shaping cell-fate outcomes and contributing to cell-to-cell heterogeneities in death decision making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.